Boston – December 9, 2015 – Cooley advised ERYTECH Pharma on a private placement of its ordinary shares to qualified investors in the United States and Europe. Gross proceeds to ERYTECH from the private placement were €25.4 million.
ERYTECH, based in Lyon, France with US headquarters in Boston, is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's ordinary shares are listed on Euronext Paris.
The Cooley team advising ERYTECH was led by partners Marc Recht and Div Gupta and included special counsel Brian Leaf and associates David Bartholomew, Courtney Thorne, Katie Kazem and Katelyn Kimber. Critical support for the private placement was provided by tax associate Stephanie Gentile and corporate partner Francis Wheeler.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.